Aldeyra Therapeutics (ALDX) vs Pliant Therapeutics (PLRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pliant Therapeutics (PLRX) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 34.6% versus a loss of 83.1%. Over five years, ALDX leads with a -88.6% price change compared with -94.4% for PLRX. Pliant Therapeutics is the larger company by market cap ($63.2 million vs $57.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | PLRX |
|---|---|---|
| Share price | $0.9604 | $1.02 |
| Market cap | $57.94M | $63.16M |
| 1-day change | +1.34% | +2.02% |
| YTD return | -81.70% | -18.03% |
| 1-year return | -83.14% | -34.64% |
| 5-year return | -88.64% | -94.44% |
| EPS (TTM) | $-0.38 | $-1.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $1.95 |
| 52-week low | $0.862 | $0.97 |
| Distance from 52-week high | -83.80% | -47.69% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +587.21% | +96.08% |
| Average volume | 1.18M | 477.96K |
| Shares outstanding | 60.33M | 61.92M |
| Employees | 6 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLRX has outperformed ALDX by 48.5 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
ALDX vs PLRX FAQ
Which is bigger, Aldeyra Therapeutics or Pliant Therapeutics?
Pliant Therapeutics (PLRX) is larger, with a market capitalization of $63.16M compared with $57.94M for Aldeyra Therapeutics (ALDX).
Which stock has performed better over the past year, ALDX or PLRX?
PLRX returned -34.64% over the past 12 months, compared with -83.14% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Pliant Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.